
Kamada (KMDA) Stock Forecast & Price Target
Kamada (KMDA) Analyst Ratings
Bulls say
Kamada Ltd is projected to achieve a year-over-year revenue increase of 13% and a 19% rise in adjusted EBITDA for fiscal year 2024, indicating robust financial growth. For 2025, the company anticipates total revenues between $178 million to $182 million and adjusted EBITDA between $38 million to $42 million, reflecting approximately 12% and 17% increases respectively, underscoring Kamada's commitment to driving growth through its proprietary and distribution segments. With a strong financial position, including an expected cash balance of $78 million, Kamada is strategically poised to attract Growth at a Reasonable Price (GARP) investors, particularly those interested in niche therapeutic opportunities.
Bears say
Kamada Ltd faces significant risks that could adversely impact its revenue and growth potential, primarily centered around the performance and regulatory approval of its core product, IH-AAT. The expected challenges in achieving peak commercial revenue estimates for AAT (IV and IH) products may stem from limited market size, penetration rates, and pricing strategies. Moreover, the enrollment difficulties in clinical studies due to the rarity of the disease heighten uncertainties regarding the success of its pipeline and overall business outlook.
This aggregate rating is based on analysts' research of Kamada and is not a guaranteed prediction by Public.com or investment advice.
Kamada (KMDA) Analyst Forecast & Price Prediction
Start investing in Kamada (KMDA)
Order type
Buy in
Order amount
Est. shares
0 shares